Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelzā� for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling
Creative Medical Technology (NASDAQ: CELZ) has received a Notice of Allowance from the USPTO for a patent application covering their ImmCelzā� treatment for heart failure and post-infarct pathological remodeling. The patent, effective until at least 2040, will protect the company's proprietary treatment delivered through an ultra-minimally invasive outpatient procedure.
The potential market is significant, with over 5 million heart failure patients in the United States and an additional 6 million patients with chronic chest pain who could benefit from the treatment. The patent strengthens Creative Medical's intellectual property portfolio in regenerative medicine and cell-based therapies.
Creative Medical Technology (NASDAQ: CELZ) ha ricevuto un Avviso di Concessione dall'USPTO per una domanda di brevetto riguardante il loro trattamento ImmCelzā� per l'insufficienza cardiaca e il rimodellamento patologico post-infartuale. Il brevetto, valido almeno fino al 2040, proteggerĆ il trattamento proprietario dell'azienda somministrato tramite una procedura ambulatoriale ultra-minimamente invasiva.
Il mercato potenziale ĆØ significativo, con oltre 5 milioni di pazienti con insufficienza cardiaca negli Stati Uniti e altri 6 milioni di pazienti con dolore toracico cronico che potrebbero beneficiare del trattamento. Il brevetto rafforza il portafoglio di proprietĆ intellettuale di Creative Medical nella medicina rigenerativa e nelle terapie a base cellulare.
Creative Medical Technology (NASDAQ: CELZ) ha recibido un Aviso de ConcesiĆ³n por parte de la USPTO para una solicitud de patente que cubre su tratamiento ImmCelzā� para insuficiencia cardĆaca y remodelaciĆ³n patolĆ³gica post-infarto. La patente, vigente al menos hasta 2040, protegerĆ” el tratamiento exclusivo de la compaƱĆa administrado mediante un procedimiento ambulatorio ultra mĆnimamente invasivo.
El mercado potencial es significativo, con mĆ”s de 5 millones de pacientes con insuficiencia cardĆaca en Estados Unidos y otros 6 millones de pacientes con dolor torĆ”cico crĆ³nico que podrĆan beneficiarse del tratamiento. La patente fortalece el portafolio de propiedad intelectual de Creative Medical en medicina regenerativa y terapias basadas en cĆ©lulas.
Creative Medical Technology (NASDAQ: CELZ)ė� ģ¬ė¶ģ � ė°� ģ¬ź·¼ź²½ģ ķ� ė³ģ ģ¬ķģ±ģ ģķ ImmCelzā� ģ¹ė£ė²�ģ� ėķ� ķ¹ķ ģ¶ģģ� ėķ� USPTOė”ė¶ķ� ķź° ķµģ§ģė„¼ ė°ģģµėė�. ģ� ķ¹ķė� ģµģ 2040ė ź¹ģ§ ģ ķØķė©°, ķģ¬ģ� ė ģ ģ¹ė£ė²ģ ģ“ģķ� ģµģ ģ¹Øģµ ģøė ģģ ģ� ķµķ“ ė³“ķøķ� ź²ģ ėė¤.
ėÆøźµ ė� 500ė§� ėŖ� ģ“ģģ� ģ¬ė¶ģ � ķģź³� ė§ģ± ķķµ ķģ 600ė§� ėŖ�ģ� ģ� ģ¹ė£ė²ģ ķķģ� ė°ģ ģ� ģģ“ ģ ģ¬ ģģ„ģ� ķ½ėė�. ģ� ķ¹ķė� ģ¬ģ ģķ ė°� ģøķ¬ źø°ė° ģ¹ė£ ė¶ģ¼ģģ Creative Medicalģ� ģ§ģ � ģ¬ģ° ķ¬ķøķ“ė¦¬ģ¤ė„¼ ź°ķķ©ėė�.
Creative Medical Technology (NASDAQ : CELZ) a reƧu un Avis d'Acceptation de l'USPTO pour une demande de brevet couvrant leur traitement ImmCelzā� pour l'insuffisance cardiaque et le remodelage pathologique post-infarctus. Le brevet, valable au moins jusqu'en 2040, protĆ©gera le traitement exclusif de l'entreprise administrĆ© par une procĆ©dure ambulatoire ultra-minimale invasive.
Le marchĆ© potentiel est important, avec plus de 5 millions de patients souffrant d'insuffisance cardiaque aux Ćtats-Unis et 6 millions de patients supplĆ©mentaires souffrant de douleurs thoraciques chroniques qui pourraient bĆ©nĆ©ficier du traitement. Ce brevet renforce le portefeuille de propriĆ©tĆ© intellectuelle de Creative Medical dans la mĆ©decine rĆ©gĆ©nĆ©rative et les thĆ©rapies Ć base de cellules.
Creative Medical Technology (NASDAQ: CELZ) hat von der USPTO eine Zulassungsmitteilung fĆ¼r eine Patentanmeldung erhalten, die ihre ImmCelzā�-Behandlung fĆ¼r Herzinsuffizienz und postinfarktbedingtes pathologisches Remodeling abdeckt. Das Patent, das mindestens bis 2040 gĆ¼ltig ist, schĆ¼tzt die firmeneigene Behandlung, die durch ein ultra-minimalinvasives ambulantes Verfahren verabreicht wird.
Der potenzielle Markt ist erheblich, mit Ć¼ber 5 Millionen Herzinsuffizienzpatienten in den Vereinigten Staaten und weiteren 6 Millionen Patienten mit chronischen Brustschmerzen, die von der Behandlung profitieren kƶnnten. Das Patent stƤrkt das geistige Eigentumsportfolio von Creative Medical im Bereich der regenerativen Medizin und zellbasierten Therapien.
- Patent protection secured until at least 2040 for ImmCelz treatment
- Large addressable market of over 11 million potential patients in the US
- Treatment delivered through ultra-minimally invasive outpatient procedure
- Strengthens company's intellectual property portfolio in regenerative medicine
- Product still in clinical-stage, not yet FDA approved
- No revenue generation from this treatment currently
PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (āCreative Medicalā� or the āCompanyā�), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, ā�Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.ā�
Once granted, the patent will be in effect until at least 2040.
The patent has broad claims to treat patients who are at risk of developing or who already have heart failure with the Companyās proprietary ImmCelz product.Ā Some patients who experience a heart attack develop post-infarct pathological remodeling, which can lead to reduced heart function and potentially result in heart failure. The total treatable heart failure population in the United States is greater than five million patients. There are also over six million patients who have chronic chest pain (refractory angina) despite maximal medical and surgical therapy who may also benefit from the ImmCelz product. The ImmCelz product is delivered to the patient via an ultra-minimally invasive outpatient procedure.
"This Notice of Allowance further strengthens our already robust intellectual property portfolio and reflects the potential of our cell-based technology to develop therapies that support the reprogramming, regrowth, and repair of the body across multiple indications,ā� said Timothy Warbington, CEO of Creative Medical. āThis latest allowance adds further value to our franchise and will help to support the continuing growth and evolution of our regenerative medicine platform."
About ImmCelzTM
Creative Medicalās ImmCelz platform utilizes a patientās own extracted immune cells that are then āreprogrammed/superchargedā� by culturing them outside the patientās body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes that this process endows the immune cells with regenerative properties (or āsuperchargesā� them) on top of their original innate functions providing them with the ability to treat multiple indications.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine solutions for multiple indications, including pain management, neurology, and urology. The company leverages cutting-edge cell therapy technologies to develop transformative treatments aimed at improving patient outcomes.
For more information, visit .
Forward Looking Statements
This news release may contain forward-looking statements including, but not limited to, comments regarding the potential for the Companyās cell-based therapies and the strength of its intellectual property portfolio. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atĀ
Contact:
Creative Medical Technology Holdings, Inc.
[email protected]
Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
Conor Rodriguez
Associate
FAQ
What patent did Creative Medical Technology (CELZ) receive for ImmCelz treatment?
How many potential patients could benefit from CELZ's ImmCelz treatment?
How is the ImmCelz treatment administered to patients?
What medical conditions does the new CELZ patent cover for ImmCelz treatment?
What is the current development stage of CELZ's ImmCelz treatment?
